Skip to content

Clinical efficacy of ischemic conditioning training in the treatment of knee osteoarthritis: a prospective, randomized controlled study

Clinical efficacy of ischemic conditioning training in the treatment of knee osteoarthritis: a prospective, randomized controlled study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084996
Enrollment
Unknown
Registered
2024-05-29
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Experimental group:Normal receive routine OA therapy medications such as glucosamine, celecoxib, etc. The affected limb was subjected to ischemic conditioning using the armbands for sphygmomanometer o
Control group:Only conventional OA medications such as glucosamine and celecoxib are accepted.

Sponsors

China-Japan Union Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Subjects were between 55 and 80 years old (including 55 and 80 years old), and gender was not limited; (2) Osteoarthritis Kellgren-Lawrence grading standard grade I-III; (3) Stable vital signs and normal liver and kidney functions; (4) Body mass index 18 = BMI = 35; (5) Clinical diagnosis to undergo total knee arthroplasty; (6) Have not participated in other clinical trials within 3 months; (7) Subjects are fully aware of the benefits and risks of this trial and are still willing to participate and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Have broken skin, vesicular swelling, soft tissue damage, and vascular damage to the lower extremities; (2) Suffering from bleeding disorders; (3) Combined with serious primary diseases such as cardiovascular, cerebrovascular, hepatic, renal and hematopoietic systems; (4) Patients with abnormal mental behavior who cannot cooperate; (5) Those who have recently taken special drugs, such as antiepileptic drugs and immunosuppressants; (6) Blood pressure >200/110 mm Hg or <90/60 mm Hg; (7) Others whom the investigators considered unsuitable for enrollment, such as those who could not undergo efficacy determination.

Design outcomes

Primary

MeasureTime frame
WOMAC score;

Secondary

MeasureTime frame
VAS score;HSS score, OARSI score;Beck Anxiety Inventory, Beck Depression Inventory;

Countries

China

Contacts

Public ContactZuo Jianlin

China-Japan Union Hospital of Jilin University

zuojl@jlu.edu.cn+86 178 4336 0886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026